Braf
Entity.
- Evidence
- 146 documents · 58 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 15 Mar 2026, last seen 2 Nov 2026
- Measured
- 3% of mentions say something specific about it; the rest only name it
- As of
- 3 Nov 2026
Where this comes from
- J Gastrointest Cancer · 2026-10-30 · Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Anal… (opens the source in a new tab)
- Inside Precision Medicine · 2026-10-19 · PGDx elio® tissue complete CDx Brings Speed and Confidence to Advanced Melanoma BRAF Testing (opens the source in a new tab)
- Medicina (Kaunas) · 2026-10-12 · Diagnostic Accuracy of VE1 Immunohistochemistry for BRAF p.V600E in Colorectal Carcinoma: A Systematic Review. (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-02 · Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis (opens the source in a new tab)
- Anticancer Drugs · 2026-09-30 · Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case r… (opens the source in a new tab)
- Clin Colorectal Cancer · 2026-09-27 · Real-world outcomes of encorafenib plus panitumumab in BRAF V600E-mutant mCRC (opens the source in a new tab)
- Crc-Digest · 2026-09-27 · FDG-PET Metabolic Patterns Differ Across RAS, BRAF, and Wild-Type Tumors (opens the source in a new tab)
- Crc-Digest · 2026-09-26 · Inflammation markers predict outcomes in RAS/BRAF wild-type mCRC on anti-EGFR therapy (opens the source in a new tab)
- Crc-Digest · 2026-09-15 · Panitumumab role in RAS and BRAF wild-type metastatic colorectal cancer (opens the source in a new tab)
- Inside Precision Medicine · 2026-09-15 · BRAF Mutation Class Influences Outcomes in NSCLC (opens the source in a new tab)
- Crc-Digest · 2026-09-11 · ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC (opens the source in a new tab)